JP2007508353A5 - - Google Patents

Download PDF

Info

Publication number
JP2007508353A5
JP2007508353A5 JP2006534713A JP2006534713A JP2007508353A5 JP 2007508353 A5 JP2007508353 A5 JP 2007508353A5 JP 2006534713 A JP2006534713 A JP 2006534713A JP 2006534713 A JP2006534713 A JP 2006534713A JP 2007508353 A5 JP2007508353 A5 JP 2007508353A5
Authority
JP
Japan
Prior art keywords
mol
pharmaceutical composition
cationic liposome
paclitaxel
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006534713A
Other languages
English (en)
Japanese (ja)
Other versions
JP5645340B2 (ja
JP2007508353A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2004/011655 external-priority patent/WO2005039533A1/en
Publication of JP2007508353A publication Critical patent/JP2007508353A/ja
Publication of JP2007508353A5 publication Critical patent/JP2007508353A5/ja
Application granted granted Critical
Publication of JP5645340B2 publication Critical patent/JP5645340B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006534713A 2003-10-15 2004-10-15 活性成分を含有するカチオンリポソームの投与方法 Expired - Fee Related JP5645340B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP03023539 2003-10-15
EP03023539.4 2003-10-15
EP04000361 2004-01-09
EP04000361.8 2004-01-09
PCT/EP2004/011655 WO2005039533A1 (en) 2003-10-15 2004-10-15 Method of administering cationic liposomes comprising an active drug

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012159071A Division JP2012229255A (ja) 2003-10-15 2012-07-17 活性成分を含有するカチオンリポソームの投与方法

Publications (3)

Publication Number Publication Date
JP2007508353A JP2007508353A (ja) 2007-04-05
JP2007508353A5 true JP2007508353A5 (https=) 2007-12-06
JP5645340B2 JP5645340B2 (ja) 2014-12-24

Family

ID=34524705

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006534713A Expired - Fee Related JP5645340B2 (ja) 2003-10-15 2004-10-15 活性成分を含有するカチオンリポソームの投与方法
JP2012159071A Pending JP2012229255A (ja) 2003-10-15 2012-07-17 活性成分を含有するカチオンリポソームの投与方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012159071A Pending JP2012229255A (ja) 2003-10-15 2012-07-17 活性成分を含有するカチオンリポソームの投与方法

Country Status (11)

Country Link
US (1) US20080063699A1 (https=)
EP (2) EP1673069B1 (https=)
JP (2) JP5645340B2 (https=)
AU (1) AU2004283464B8 (https=)
CA (1) CA2542217C (https=)
DK (1) DK2286794T3 (https=)
ES (1) ES2574231T3 (https=)
HU (1) HUE028648T2 (https=)
PL (1) PL2286794T3 (https=)
PT (1) PT2286794T (https=)
WO (1) WO2005039533A1 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
US20050255154A1 (en) 2004-05-11 2005-11-17 Lena Pereswetoff-Morath Method and composition for treating rhinitis
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
SI1853250T1 (sl) 2005-02-18 2012-01-31 Abraxis Bioscience Llc Kombinacije in reĹľimi dajanja terapevtskih sredstev in kombinirana terapija
JP5700909B2 (ja) * 2005-05-04 2015-04-15 メディゲーネ アクチエンゲゼルシャフトMediGene AG パクリタキセルを含む陽イオン性リポソーム製剤を投与する方法
DK1919450T3 (da) * 2005-09-01 2014-09-15 Meda Ab Antihistamin- og corticosteroidholdig liposomsammensætning og dens anvendelse til fremstilling af et lægemiddel til behandling af rhinitis og beslægtede lidelser
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
KR100658436B1 (ko) * 2005-12-09 2006-12-27 한국화학연구원 아데노실코발라민 함유 피부질환 치료용 외용제 조성물
MX2008011978A (es) 2006-03-22 2009-04-22 Medigene Ag Tratamiento del cancer de seno negativo al triple receptor.
US20090232731A1 (en) * 2006-05-18 2009-09-17 Martin Funk Cationic Liposomal Preparations for the Treatment of Rheumatoid Arthritis
KR20130028727A (ko) 2010-03-29 2013-03-19 아브락시스 바이오사이언스, 엘엘씨 치료제의 약물 전달 및 유효성 향상 방법
NZ717490A (en) 2010-03-29 2017-12-22 Abraxis Bioscience Llc Methods of treating cancer
EP2394640A1 (en) 2010-05-21 2011-12-14 MediGene AG Improved liposomal formulations of lipophilic compounds
BR112012030909A2 (pt) 2010-06-04 2020-08-18 Abraxis Bioscience, Llc métodos de tratamento de câncer pancreático
US20120028335A1 (en) 2010-07-28 2012-02-02 Life Technologies Corporation Anti-viral azide-containing compounds
EP2598128B1 (en) 2010-07-28 2018-03-28 Life Technologies Corporation Anti- viral azide-containing compounds
US20140005160A1 (en) * 2010-12-01 2014-01-02 Hooshmand SHESHBARADARAN Method for Treating Refractory Cancer
HRP20211595T1 (hr) 2011-05-24 2022-01-21 BioNTech SE Individualizirana cjepiva protiv raka
SG11201404361UA (en) 2012-01-26 2014-09-26 Life Technologies Corp Methods for increasing the infectivity of viruses
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
WO2014082729A1 (en) 2012-11-28 2014-06-05 Biontech Ag Individualized vaccines for cancer
DE102013009744A1 (de) * 2013-03-26 2014-10-02 Forschungszentrum Jülich GmbH Fusionsmischung zur lipidhaltigen Membranmodifikation einer beliebigen Lipidmembran, einer Zellmembran, einem Bestandteil einer Zellmembran oder einer von den übrigen Zell- Bestandteilen getrennten Zellmembran in vivo oder in vitro
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
EP3302423B1 (en) 2015-06-04 2022-05-25 Crititech, Inc. Particle production system and particle collection device
CA2998483C (en) 2015-09-16 2022-09-06 Dfb Soria, Llc Delivery of drug nanoparticles and methods of use thereof
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
BR112018069628A2 (pt) 2016-04-04 2019-02-12 Crititech, Inc. métodos para tratamento de tumor sólido
EP3538074B1 (en) * 2016-11-11 2023-07-26 Western University Of Health Sciences Methods of treating upper tract urothelial carcinomas
TWI852903B (zh) * 2017-01-05 2024-08-21 杏國新藥股份有限公司 胰臟癌治療
WO2018170196A1 (en) 2017-03-15 2018-09-20 Dfb Soria, Llc Topical therapy for the treatment of skin malignancies using nanoparticles of taxanes
EP3615145B1 (en) 2017-06-09 2024-05-15 Crititech, Inc. Compositions for use in the treatment of epithelial cysts by intracystic injection of antineoplastic particles
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
WO2018231908A1 (en) 2017-06-14 2018-12-20 Crititech, Inc. Methods for treating lung disorders
KR20250057947A (ko) 2017-10-03 2025-04-29 크리티테크, 인크. 암의 치료를 위한 면역치료제의 전신 전달과 조합된 항신생물성 입자의 국소 전달
US11497726B2 (en) 2018-03-16 2022-11-15 Dfb Soria, Ll. Topical therapy for the treatment of cervical intraepithelial neoplasia (CIN) and cervical cancer using nanoparticles of taxanes
EP4659741A1 (en) * 2023-01-31 2025-12-10 CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Use of paclitaxel cationic liposome in treating tumors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1254135B (it) 1992-01-16 1995-09-08 Sigma Tau Ind Farmaceuti Esteri di acil carnitine con alcooli alifatici a lunga catena e composizioni farmaceutiche che li contengono, ad attivita' antibatterica.
EP0706373B1 (en) 1992-03-23 2000-07-19 Georgetown University Liposome encapsulated taxol and a method of using the same
DE4447770C2 (de) * 1994-08-20 2002-12-19 Max Delbrueck Centrum Verfahren zur Herstellung von liposomal verkapseltem Taxol
US5837283A (en) * 1997-03-12 1998-11-17 The Regents Of The University Of California Cationic lipid compositions targeting angiogenic endothelial cells
US7112338B2 (en) * 1997-03-12 2006-09-26 The Regents Of The University Of California Cationic liposome delivery of taxanes to angiogenic blood vessels
US6146659A (en) * 1998-07-01 2000-11-14 Neopharm, Inc. Method of administering liposomal encapsulated taxane
US7314637B1 (en) * 1999-06-29 2008-01-01 Neopharm, Inc. Method of administering liposomal encapsulated taxane
MXPA02002579A (es) * 1999-09-09 2003-10-14 Univ California Entrega de liposomas cationicas de taxanos a vasos sanguineos angiogenicos.
UY27185A1 (es) * 2001-02-28 2002-09-30 Bristol Myers Squibb Co Dosificación metronómica de taxanos
EP1530465B2 (en) * 2002-06-26 2015-12-16 MediGene AG Method of producing a cationic liposomal preparation comprising a lipophilic compound
WO2004002455A1 (en) * 2002-06-26 2004-01-08 Medigene Oncology Gmbh Novel method of stabilizing diagnostic and therapeutic compounds in a cationic carrier system

Similar Documents

Publication Publication Date Title
JP2007508353A5 (https=)
JP5704788B2 (ja) 癌の治療および過剰増殖性疾患の治療のための、免疫遺伝子療法と化学療法の組み合わせ
JP2018528184A5 (https=)
JP2011144190A (ja) 抗癌剤の効果増強剤
CN115487187B (zh) 一种用于治疗胃癌的喹啉衍生物
JP6855488B2 (ja) 食道癌を治療するためのキノリン誘導体の使用とその治療方法、医薬組成物及びキット
TWI522105B (zh) 偏亞砷酸鈉於治療癌疼痛及炎症之用途
JP2003528920A (ja) 血管損傷性活性を有する併用療法
JP2010043115A (ja) 腫瘍転移および癌の治療における5−フルオロウラシルの有効性の増強
CN101687104A (zh) 包括长春氟宁和曲妥单抗的癌症治疗联合疗法
JP2009536956A (ja) 抗癌治療法
JP2008540364A5 (https=)
CN102438608A (zh) 包含ave8062和索拉非尼的抗肿瘤组合
O'Shaughnessy et al. Current status of paclitaxel in the treatment of breast cancer
CA2483826A1 (en) Epothilone derivative for the treatment of hepatoma and other cancer diseases
CN101652138A (zh) 1-取代芳基-2(1h)-吡啶酮化合物的新医药用途
Tralongo et al. Chemotherapy in frail elderly patients with hormone-refractory prostate cancer: A “real world” experience
CN104968340A (zh) 治疗肝脏疾病或病状的用途和方法
Qu et al. Oral fruquintinib combined with tegafur-gimeracil-oteracil potassium for advanced colorectal cancer to obtain longer progression-free survival: A case report
Kuo et al. Functionalized drug-gene delivery materials to transport inhibitor of apoptosis protein antagonists for tumor malignancy management
CN113993515B (zh) 使用藏红花酸治疗实体肿瘤的方法
EP2826482A1 (en) Novel antitumor agent comprising combination of three agents
KR20140022856A (ko) 치료적 요법
JPWO2023035611A5 (https=)
JPWO2022074124A5 (https=)